Mindfulness-orienteret Recovery Enhancement (MERE) til kræftsmertelindring
Tilpasning af Mindfulness-orienteret Recovery Enhancement (MERE) til kræftsmertelindring: MORE Relief Trial
The purpose of this study is to evaluate whether or not mindfulness-based interventions/MBIs may help reduce chronic pain in participants who have cancer-related chronic pain. MBIs are therapeutic programs that use mindfulness meditation practices to help people focus on the present moment, as well as encourage acceptance of thoughts, emotions, and body sensations. The researchers think that an MBI treatment called Mindfulness-oriented Recovery Enhancement (MORE) may help people who are experiencing cancer-related chronic pain.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- English speaking
- Age ≥ 18 years or older
- A history of cancer with no restrictions placed on type of cancer
- Determined to be either no-evidence of disease or stable oncological disease by referring or study physicians/advanced practice providers
- Having a pain (musculoskeletal, generalized, or neuropathic) rating of 4 or greater in worst pain on a 0-10 numerical rating scale in the preceding week
- Having had pain for at least 3 months and at least 15 days with pain in the preceding 30 days
- Willing to adhere to all study-related procedures, including randomization to one of two treatment arms: MORE or WLC
- Ability to attend video-call session and a quiet/private location
Exclusion Criteria:
- Active suicidality or schizophrenia
- Plan to initiate palliative radiation or interventional pain procedure within the next 12 weeks
- Cognitive impairment preventing completing PRO independently or participate in virtual MORE as evaluated by study clinicians
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Wait List Control (WLC) Usual Care Procedure
Participants in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers. |
Participants in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers. |
|
Eksperimentel: 16-hour MORE treatments
Patients in the 16-hour MORE format will receive one 2hrs treatment a week for 8 consecutive weeks (as per study schema: from week 1 to week 8). |
MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time |
|
Eksperimentel: 8-hour MORE treatments
Patients in the 8-hour MORE format will receive one 2hrs treatment a week for 4 consecutive weeks (as per study schema: from week 1 to week 4). |
MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time |
|
Eksperimentel: 2-hour MORE treatments
Patients in the 2-hour MORE format will receive one 2hrs treatment (as per study schema: in week 1). |
MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Rate of participant enrollment to the study
Tidsramme: 12 months
|
Feasibility of the intervention will be determined by Rate of participant enrollment to the study |
12 months
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Jun Mao, MD, MSCE, Memorial Sloan Kettering Cancer Center
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Smerte
- Neurologiske manifestationer
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Kræftsmerter
- Kronisk smerte
- Sundhedstjenester Administration
- Sundhedsvæsenets kvalitet, adgang og evaluering
- Terapeutik
- Sundhedskvalitet
- Kvalitetsindikatorer, sundhedsvæsenet
- Patientplejestyring
- Sygdomsstyring
- Standard for pleje
- Smertehåndtering
Andre undersøgelses-id-numre
- 23-082
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .